• Home
  • News
  • Contact
Rokote Laboratories Finland Ltd received funding from Sitra to prepare decentralised clinical trial

Rokote Laboratories Finland Ltd received funding from Sitra to prepare decentralised clinical trial

by Okapit | Dec 15, 2022 | Uncategorized

The purpose of the funding granted by Sitra is to expedite the popularisation of decentralised and virtual research methods in Finland. Rokote Laboratories Finland Ltd will use the funding to prepare a research plan and application for a phase 1a clinical trial of a...

Rokote Laboratories Finland Ltd updates its vaccine to be more effective against new virus variants too

by Okapit | Jun 6, 2022 | Uncategorized

Rokote Laboratories Finland Ltd has decided to update its intranasal vaccine because the SARS-CoV-2 BA.4 and BA.5 virus variants have become more common. Therefore, the launch of the clinical trials will be moved to 2023. SARS-CoV-2 appears to be here to stay and able...
Next Entries »

Recent Posts

  • Terhi Reunama Appointed as Head of Clinical Trial Operations
  • Our Nasal COVID-19 Vaccine Moves to First Human Trials
  • Rokote Laboratories Finland Oy Submits First Clinical Trial Application
  • Rokote Laboratories Finland Oy Announces CEO Transition and Future Plans
  • Professor Seppo Ylä-Herttuala received the 2023 Outstanding Achievement Award from ESGCT

Recent Comments

No comments to show.

Rokote Laboratories Finland Oy

Company ID: 3155372-4
VAT: FI31553724

  • Follow
Invoicing details